MYL:NSD-Mylan N.V (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 15.05

Change

-0.64 (-4.08)%

Market Cap

USD 8.11B

Volume

3.51M

Average Target Price

USD 17.67 (+17.39%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

-1.65 (-2.97%)

USD2.37B 870.20 69.93
CRON Cronos Group Inc

-0.30 (-5.15%)

USD2.03B 2.89 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.07 (-0.73%)

USD1.54B 15.31 12.76
ENDP Endo International plc

-0.24 (-4.15%)

USD1.33B N/A 8.81
APHA Aphria Inc

+0.02 (+0.44%)

USD1.31B 57.50 454.68
ATNX Athenex, Inc

+0.23 (+2.01%)

USD1.07B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

-0.39 (-1.94%)

USD1.06B 9.15 5.82
AMPH Amphastar Pharmaceuticals, Inc

-0.55 (-2.64%)

USD0.99B 260.50 31.99
TLRY Tilray, Inc

-0.87 (-12.93%)

USD0.90B N/A N/A

ETFs Containing MYL

Symbol Name Weight Mer Price(Change) Market Cap
GNRX VanEck Vectors Generic Dr.. 0.00 % 0.55 %

N/A

USD3.35M
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-2.16 (-1.28%)

USD0.36B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.12% 53% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.12% 53% F 28% F
Trailing 12 Months  
Capital Gain -20.66% 60% D- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.66% 60% D- 29% F
Trailing 5 Years  
Capital Gain -66.47% 36% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.47% 36% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -18.95% N/A N/A 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.95% N/A N/A 10% F
Risk Return Profile  
Volatility (Standard Deviation) 20.02% N/A N/A 70% C-
Risk Adjusted Return -94.64% N/A N/A 4% F
Market Capitalization 8.11B 100% A+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.43 40% F 34% F
Price/Book Ratio 0.69 94% A 90% A-
Price / Cash Flow Ratio 4.50 27% F 47% F
EV/EBITDA 7.35 77% C+ 76% C
Management Effectiveness  
Return on Equity 2.29% 89% B+ 57% F
Return on Invested Capital 1.73% 83% B 50% F
Return on Assets 3.53% 88% B+ 77% C+
Debt to Equity Ratio 94.37% 24% F 25% F
Technical Ratios  
Short Ratio 8.07 42% F 15% F
Short Percent 11.20% 39% F 21% F
Beta 1.47 42% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector